While the oncogenic mutant K-Ras is found in approximately 88% of pancreatic, 50% of colorectal, and 32% of lung cancers (Prior et al., 2020), no anti–K-Ras drugs are currently available in clinics. Here, KRAS is linked to lung carcinoma.